SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-085605
Filing Date
2023-07-31
Accepted
2023-07-31 08:07:29
Documents
13
Period of Report
2023-07-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2322342d1_8k.htm   iXBRL 8-K 38438
2 EXHIBIT 2.1 tm2322342d1_ex2-1.htm EX-2.1 526528
  Complete submission text file 0001104659-23-085605.txt   853312

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20230730.xsd EX-101.SCH 3012
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20230730_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20230730_pre.xml EX-101.PRE 22357
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2322342d1_8k_htm.xml XML 3473
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 231125091
SIC: 2834 Pharmaceutical Preparations